期刊
THERANOSTICS
卷 6, 期 9, 页码 1425-1439出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.15359
关键词
Circulating tumor cell
资金
- National Institutes of Health [R21CA151159, R33CA157396, P01CA168585, R33CA174562, P01CA098912, U01CA198900, R44CA180482]
- Department of Defense [W81XWH-11-1-0422, PC151088]
- Prostate Cancer Foundation
- UCLA Prostate Cancer SPORE Program
- Steven Spielberg Discovery Fund in Prostate Cancer Research
- St. Anthony Prostate Cancer Research Fund
- CD McKinnon Memorial Fund for Neuroendocrine Prostate Cancer
- Berns Family Fund
Liquid biopsy of tumor through isolation of circulating tumor cells (CTCs) allows non-invasive, repetitive, and systemic sampling of disease. Although detecting and enumerating CTCs is of prognostic significance in metastatic cancer, it is conceivable that performing molecular and functional characterization on CTCs will reveal unprecedented insight into the pathogenic mechanisms driving lethal disease. Nanomaterial-embedded cancer diagnostic platforms, i.e., NanoVelcro CTC Assays represent a unique rare-cell sorting method that enables detection isolation, and characterization of CTCs in peripheral blood, providing an opportunity to noninvasively monitor disease progression in individual cancer patients. Over the past decade, a series of NanoVelcro CTC Assays has been demonstrated for exploring the full potential of CTCs as a clinical biomarker, including CTC enumeration, phenotyping, genotyping and expression profiling. In this review article, the authors will briefly introduce the development of three generations of NanoVelcro CTC Assays, and highlight the clinical applications of each generation for various types of solid cancers, including prostate cancer, pancreatic cancer, lung cancer, and melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据